Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA)
Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB™ Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME™ or XIENCE Xpedition™) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Amsterdam, Pays-Bas
- Onze Lieve Vrouwe Gasthuis
-
Dordrecht, Pays-Bas
- Albert Schweitzer Hospital
-
Hilversum, Pays-Bas
- Tergooi Hospital
-
Leeuwarden, Pays-Bas
- Medical center Leeuwarden
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Pays-Bas, 1105 AZ
- AMC
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subject is an acceptable candidate for treatment with a drug-eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions and the Instructions for Use of the ABSORB BVS strategy and XIENCE family.
- Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the ABSORB BVS strategy and he/she or his/her legally authorized representative provides written informed consent prior to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee.
Exclusion Criteria:
- Subject is younger than 18 years of age
- Subject has a true bifurcation lesion where a priori two scaffold/stent strategy is planned.
- Unsuccessful predilation of one or more of the planned lesion to be treated.
- Planned treatment of in-stent restenosis of a previously placed metallic stent.
- Subject has one or more lesion planned to be treated with a scaffold/stent diameter size smaller than 2.5 mm or greater than 4.0 mm.
- Subject has one or more lesion planned to be treated with a stent/scaffold length greater than 70 mm and/or overlapping of four or more scaffolds/stents.
- Subject has known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel, prasugrel and ticagrelor, inclusive), everolimus, poly (L-lactide), poly (DL-lactide), cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be adequately pre-medicated.
- Subjects pregnant or nursing subjects and those who plan pregnancy in the period up to 2 years following index procedure. (Female subjects of child-bearing potential must have a negative pregnancy test done within 28 days prior to the index procedure and contraception must be used during participation in this trial)
- Subjects with a limited life expectancy less than one year.
- Subjects with factors that impede clinical follow-up (e.g. no fixed abode).
- Subject is already participating in another clinical investigation that has not yet reached its primary endpoint.
- Subject is belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff or sponsor staff) or subject unable to read or write.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur actif: ABSORB BVS™
Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
|
Bioresorbable scaffold
Autres noms:
|
|
Comparateur actif: XIENCE™
XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
|
Drug eluting metallic stent
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Target Vessel Failure (TVF)
Délai: 2 years
|
The primary composite endpoint is the device-oriented composite of target vessel failure (TVF):
|
2 years
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Device success
Délai: 1 day
|
Successful delivery and deployment of the first study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 20% by quantitative coronary angiography (QCA) and thrombolysis in myocardial infarction (TIMI) 3 flow grade of the treated vessel.
|
1 day
|
|
Procedural success
Délai: 1 day
|
Achievement of final in-scaffold/stent residual stenosis of less than 20% by QCA and TIMI 3 flow grade of the treated vessel with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat Target Lesion Revascularization during the hospital stay.
|
1 day
|
|
Target vessel failure (TVF)
Délai: 30 days, and 1, 3, 4 and 5 years
|
Cardiac death, MI (not clearly attributable to a nontarget vessel) or target vessel revascularization
|
30 days, and 1, 3, 4 and 5 years
|
|
Target lesion failure
Délai: 30 days, and 1, 2, 3, 4 and 5 years
|
Cardiac death, MI (not clearly attributable to a nontarget vessel) or target lesion revascularization
|
30 days, and 1, 2, 3, 4 and 5 years
|
|
All revascularizations
Délai: 5 year
|
5 year
|
|
|
Major adverse cardiac events
Délai: 30 days, and 1, 2, 3, 4 and 5 years
|
All-cause mortality, any MI, any repeat revascularization
|
30 days, and 1, 2, 3, 4 and 5 years
|
|
All cause mortality
Délai: 30 days, 1 year, 2, 3, 4 and 5 years
|
30 days, 1 year, 2, 3, 4 and 5 years
|
|
|
Myocardial Infarction
Délai: 30 days, 1, 2, 3, 4 and 5 years
|
Q-wave Myocardial Infarction (QMI) and non Q-wave Myocardial Infarction (nonQMI)/target-vessel myocardial infarction (TVMI) and non-TVMI
|
30 days, 1, 2, 3, 4 and 5 years
|
|
Target Lesion Revascularization (TLR)
Délai: 30 days, 1 year, 2, 3, 4 and 5 years
|
30 days, 1 year, 2, 3, 4 and 5 years
|
|
|
Target Vessel Revascularization (TVR)
Délai: 30 days, 1 year, 2, 3, 4 and 5 years
|
30 days, 1 year, 2, 3, 4 and 5 years
|
|
|
Non-Target Vessel Revascularization (NTVR)
Délai: 30 days, 1 year, 2, 3, 4 and 5 years
|
30 days, 1 year, 2, 3, 4 and 5 years
|
|
|
Scaffold/Stent Thrombosis
Délai: 30 days, 1, 2, 3, 4 and 5 years
|
acute, subacute, late/definite and probable
|
30 days, 1, 2, 3, 4 and 5 years
|
|
Seattle Angina Questionnaire (SAQ)
Délai: 1 year and 2 years
|
1 year and 2 years
|
|
|
Quality of Life Questionnaire (QOL)
Délai: 1 year and 2 years
|
1 year and 2 years
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Directeur d'études: Joanna Wykrzykowska, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Chercheur principal: Rob de Winter, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Chercheur principal: Jan Piek, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Chercheur principal: Jan Tijssen, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Chercheur principal: Jose Henriques, MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publications et liens utiles
Publications générales
- Woudstra P, Grundeken MJ, Kraak RP, Hassell ME, Arkenbout EK, Baan J Jr, Vis MM, Koch KT, Tijssen JG, Piek JJ, de Winter RJ, Henriques JP, Wykrzykowska JJ. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design. Am Heart J. 2014 Feb;167(2):133-40. doi: 10.1016/j.ahj.2013.09.017. Epub 2013 Oct 17.
- Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Garcia-Garcia HM, Kraak R, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. EuroIntervention. 2022 Mar 18;17(16):1340-1347. doi: 10.4244/EIJ-D-21-00419.
- Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RYG, Koch KT, Baan J Jr, Vis MM, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS; AIDA Investigators. Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Anticipé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Ischémie
- Processus pathologiques
- Nécrose
- Ischémie myocardique
- Maladies cardiaques
- Maladies cardiovasculaires
- Maladies vasculaires
- Artériosclérose
- Maladies artérielles occlusives
- Maladie coronarienne
- Infarctus du myocarde
- Infarctus
- Maladie de l'artère coronaire
- Effets physiologiques des médicaments
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Évérolimus
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- COR 10341
- AIDA trial (Identificateur de registre: AIDA trial)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .